Machine Learning–Derived Baseline Visual Field Patterns Predict Future Glaucoma Onset in the Ocular Hypertension Treatment Study
Investigative Opthalmology & Visual Science · 23.02.2024 · 65 (2) · 35
DOI: 10.1167/iovs.65.2.35 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Opthalmology & Visual Science, erschienen am 23.02.2024. Verfasst von Rishabh K Singh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Ocular Hypertension, Optic Disk. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Purpose
The Ocular Hypertension Treatment Study (OHTS) identified risk factors for primary open-angle glaucoma (POAG) in patients with ocular hypertension, including pattern standard deviation (PSD). Archetypal analysis, an unsupervised machine learning method, may offer a more interpretable approach to risk stratification by identifying patterns in baseline visual fields (VFs).
Methods
There were 3272 eyes available in the OHTS. Archetypal analysis was applied using 24-2 baseline VFs, and model selection was performed with cross-validation. Decomposition coefficients for archetypes (ATs) were calculated. A penalized Cox proportional hazards model was implemented to select discriminative ATs. The AT model was compared to the OHTS model. Associations were identified between ATs with both POAG onset and VF progression, defined by mean deviation change per year.
Results
We selected 8494 baseline VFs. Optimal AT count was 19. The highest prevalence ATs were AT9, AT11, and AT7. The AT-based prediction model had a C-index of 0.75 for POAG onset. Multivariable models demonstrated that a one-interquartile range increase in the AT5 (hazard ratio [HR] = 1.14; 95% confidence interval [CI], 1.04-1.25), AT8 (HR = 1.22; 95% CI, 1.09-1.37), AT15 (HR = 1.26; 95% CI, 1.12-1.41), and AT17 (HR = 1.17; 95% CI, 1.03-1.31) coefficients conferred increased risk of POAG onset. AT5, AT10, and AT14 were significantly associated with rapid VF progression. In a subgroup analysis by high-risk ATs (>95th percentile or
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
- Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, United States.
- Tufts University School of Medicine, Boston, Massachusetts, United States.
- Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States.
- Washington University School of Medicine, St. Louis, Missouri, United States.
- Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Förderung
- NEI NIH HHS
Zitieren
APA
Singh, R. K., Smith, S., Fingert, J., Gordon, M., Kass, M., Scheetz, T., Segrè, A. V., Wiggs, J., Elze, T., & Zebardast, N. (2024). Machine Learning–Derived Baseline Visual Field Patterns Predict Future Glaucoma Onset in the Ocular Hypertension Treatment Study. Investigative Opthalmology & Visual Science, 65(2), 35. https://doi.org/10.1167/iovs.65.2.35
Vancouver
Singh RK, Smith S, Fingert J, Gordon M, Kass M, Scheetz T, et al. Machine Learning–Derived Baseline Visual Field Patterns Predict Future Glaucoma Onset in the Ocular Hypertension Treatment Study. Investigative Opthalmology & Visual Science. 2024;65(2):35. doi:10.1167/iovs.65.2.35
BibTeX
@article{Singh2024,
author = {Singh, Rishabh K and Smith, Sophie and Fingert, John and Gordon, Mae and Kass, Michael and Scheetz, Todd and Segrè, Ayellet V and Wiggs, Janey and Elze, Tobias and Zebardast, Nazlee},
title = {Machine Learning–Derived Baseline Visual Field Patterns Predict Future Glaucoma Onset in the Ocular Hypertension Treatment Study},
journal = {Investigative Opthalmology & Visual Science},
year = {2024},
volume = {65},
number = {2},
pages = {35},
doi = {10.1167/iovs.65.2.35}
}
EUVIMED